Key facts
- It has raised $68.3M; the latest was Early Stage VC ($68.3M) in Dec 2024.
- Notable investors include Frazier Healthcare Partners, Novartis Venture Fund, RTW Investments, Droia Ventures, RV Invest — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Alesta Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Alesta Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alesta Therapeutics
Developer of small-molecule biotech program designed for the development of innovative therapies targeting synthetic lethal metabolic dependencies in cancer. The company targets a control mechanism involved in the stress response pathways required for cancer cell survival, enabling patients to shut down pathways that have a particular dependency on cancer cell growth.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Founded
- 2021
- Employees
- 7
- Website
- alestatherapeutics.com/
- Ownership
- Privately Held (backing)
Alesta Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alesta Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alesta Therapeutics in its N-PORT filings yet. We sweep new filings monthly.